WallStSmart

Insmed Inc (INSM)vsDisc Medicine Inc. (IRON)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IRON leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

IRON

Avoid

27

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 2/9Altman Z: 3.92

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

IRON1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
3.9210/10

Safe zone — low bankruptcy risk

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

IRON4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : IRON

The strongest argument for IRON centers on Altman Z-Score.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : IRON

The primary concerns for IRON are Revenue Growth, EPS Growth, Profit Margin.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while IRON is a value play — different risk/reward profiles.

IRON carries more volatility with a beta of 2.66 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

IRON generates stronger free cash flow (-43M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Disc Medicine Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company is headquartered in Watertown, Massachusetts.

Want to dig deeper into these stocks?